0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Regeneron Pharmaceuticals is back in focus after a refreshed valuation framework lifted the modelled fair value estimate from US$821.12 to US$873.78 per share, a step up that pushes implied targets closer to the high US$800s and low US$900s seen in recent research. This shift lines up with analysts debating how much of Dupixent and the broader pipeline story is already in the price, with bullish and cautious voices reading the same data very differently. As you read on, you will see how to interpret these moving targets and keep track of the evolving narrative around the stock. Stay updated as the Fair Value for Regeneron Pharmaceuticals shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Regeneron Pharmaceuticals. What Wall Street Has Been Saying ?? Bullish Takeaways Barclays started coverage on Regeneron with an Overweight rating and a US$923 price target, arguing that the market is underestimating profit [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Regeneron Pharmaceuticals is back in focus after a refreshed valuation framework lifted the modelled fair value estimate from US$821.12 to US$873.78 per share, a step up that pushes implied targets closer to the high US$800s and low US$900s seen in recent research. This shift lines up with analysts debating how much of Dupixent and the broader pipeline story is already in the price, with bullish and cautious voices reading the same data very differently. As you read on, you will see how to interpret these moving targets and keep track of the evolving narrative around the stock. Stay updated as the Fair Value for Regeneron Pharmaceuticals shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Regeneron Pharmaceuticals. What Wall Street Has Been Saying ?? Bullish Takeaways Barclays started coverage on Regeneron with an Overweight rating and a US$923 price target, arguing that the market is underestimating profit [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS